As shown in Figure 2, activated TGF-β signaling by exogenous TGF-β1 only enhanced the cell motility of the parental GBM cells (51.8 ± 3.29% vs. 39.7 ± 3.26%, p = 0.0438 for 1306MG; 54.4 ± 5.18% vs. 41.0 ± 2.63%, p = 0.0424 for U87MG) while exogenous TGF-β1 did not affect the cell motility of therapeutic-resistant GBM cells (RR and RTR) (29.9 ± 2.17% vs. 28.8 ± 2.48%, p = 0.7663 for 3.5GR6, 50.5 ± 6.09% vs. 45.5 ± 3.68%, p = 0.3549 for R6T3; 40.7 ± 3.39% vs. 32.0 ± 4.27%, p = 0.0732 for 2GR4, 32.3 ± 2.91% vs. 35.4 ± 6.58%, p = 0.6075 for R4T3). The gene discussed is TGFB1; the disease is glioblastoma.